Co-Authors
This is a "connection" page, showing publications co-authored by Lawrence Kushi and Laurel Habel.
Connection Strength
1.052
-
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
Score: 0.178
-
Unraveling the genetic landscape of susceptibility to multiple primary cancers. medRxiv. 2024 Oct 30.
Score: 0.062
-
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. PLoS One. 2024; 19(6):e0303303.
Score: 0.060
-
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. medRxiv. 2024 Feb 02.
Score: 0.059
-
Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study. Radiology. 2023 06; 307(5):e222733.
Score: 0.056
-
Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies. BMC Med. 2022 10 06; 20(1):332.
Score: 0.054
-
Telehealth for Preoperative Evaluation of Patients With Breast Cancer During the COVID-19 Pandemic. Perm J. 2022 06 29; 26(2):54-63.
Score: 0.053
-
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system. Breast Cancer Res Treat. 2022 Jan 06.
Score: 0.051
-
Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun. 2021 02 12; 12(1):970.
Score: 0.048
-
Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat Commun. 2020 09 04; 11(1):4423.
Score: 0.046
-
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Res. 2016 09 15; 76(18):5415-22.
Score: 0.035
-
Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J Clin Oncol. 2016 08 10; 34(23):2743-9.
Score: 0.035
-
Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care. 2016 05 01; 22(5):e153-60.
Score: 0.034
-
Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.032
-
Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015 Apr 14; 15:278.
Score: 0.032
-
Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015 Jan; 11(1):e1004930.
Score: 0.032
-
Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014 Apr; 144(3):689-99.
Score: 0.030
-
Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):714-24.
Score: 0.030
-
Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
Score: 0.030
-
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013 Jan; 137(1):247-60.
Score: 0.027
-
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
Score: 0.025
-
Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2011 Nov; 130(1):195-205.
Score: 0.024
-
Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008 Apr 16; 100(8):597-8; author reply 599.
Score: 0.020